143 related articles for article (PubMed ID: 11165123)
1. Science and serendipity in cancer research.
Smyth JF
Eur J Cancer; 2001 Jan; 37(1):8. PubMed ID: 11165123
[No Abstract] [Full Text] [Related]
2. Trabectedin: ET 743, ecteinascidin 743, Yondelis.
Drugs R D; 2003; 4(1):75-81. PubMed ID: 12568645
[No Abstract] [Full Text] [Related]
3. Orphan anticancer drug rejected.
Burton A
Lancet Oncol; 2003 Sep; 4(9):524. PubMed ID: 12965283
[No Abstract] [Full Text] [Related]
4. Progress in the development and acquisition of anticancer agents from marine sources.
Amador ML; Jimeno J; Paz-Ares L; Cortes-Funes H; Hidalgo M
Ann Oncol; 2003 Nov; 14(11):1607-15. PubMed ID: 14581267
[No Abstract] [Full Text] [Related]
5. Trabectedin in ovarian cancer: could we expect more?
Sessa C; D'Incalci M
Ann Oncol; 2011 Jan; 22(1):7-8. PubMed ID: 21059638
[No Abstract] [Full Text] [Related]
6. Trabectedin and ovarian cancer (continued).
Prescrire Int; 2011 Oct; 20(120):249-50. PubMed ID: 21970099
[No Abstract] [Full Text] [Related]
7. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
Aune GJ; Furuta T; Pommier Y
Anticancer Drugs; 2002 Jul; 13(6):545-55. PubMed ID: 12172500
[TBL] [Abstract][Full Text] [Related]
8. Treating breast cancer with trabectedin: a new arsenal.
Malik L
Ann Oncol; 2014 Oct; 25(10):2094-2095. PubMed ID: 25057176
[No Abstract] [Full Text] [Related]
9. [Ecteinascidin 743].
Lansiaux A; Bailly C
Bull Cancer; 1999 Feb; 86(2):139-41. PubMed ID: 10094523
[No Abstract] [Full Text] [Related]
10. Trabectedin.
Chuk MK; Balis FM; Fox E
Oncologist; 2009 Aug; 14(8):794-9. PubMed ID: 19684073
[No Abstract] [Full Text] [Related]
11. Reply to the letter to the editor 'treating breast cancer with trabectedin: a new arsenal' by L. Malik.
Delaloge S; Cullell-Young M
Ann Oncol; 2014 Oct; 25(10):2095. PubMed ID: 25057170
[No Abstract] [Full Text] [Related]
12. Trabectedin and ovarian cancer: statistical trickery.
Prescrire Int; 2011 Apr; 20(115):93. PubMed ID: 21648209
[No Abstract] [Full Text] [Related]
13. Beyond clinical trials in advanced soft tissue sarcoma: what to expect from trabectedin treatment? Foreword.
Reichardt P
Future Oncol; 2015; 11(11 Suppl):1. PubMed ID: 26043309
[No Abstract] [Full Text] [Related]
14. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
Sessa C; De Braud F; Perotti A; Bauer J; Curigliano G; Noberasco C; Zanaboni F; Gianni L; Marsoni S; Jimeno J; D'Incalci M; Dall'รณ E; Colombo N
J Clin Oncol; 2005 Mar; 23(9):1867-74. PubMed ID: 15774779
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin--a targeted chemotherapy?
von Mehren M
Lancet Oncol; 2007 Jul; 8(7):565-7. PubMed ID: 17613417
[No Abstract] [Full Text] [Related]
16. [Perspectives on the oncologist pharmacopoeia].
Lansiaux A; Bailly C
Bull Cancer; 2003 Jan; 90(1):25-30. PubMed ID: 12609801
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin for the treatment of breast cancer.
D'Incalci M; Zambelli A
Expert Opin Investig Drugs; 2016; 25(1):105-15. PubMed ID: 26592307
[TBL] [Abstract][Full Text] [Related]
18. Biology of ovarian cancer and trabectedin mechanism of action.
Ray-Coquard I
Future Oncol; 2013 Dec; 9(12 Suppl):11-7. PubMed ID: 24195525
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin for the management of soft-tissue sarcoma.
Boudou L; Baconnier M; Blay JY; Lombard-Bohas C; Cassier PA
Expert Rev Anticancer Ther; 2009 Jun; 9(6):727-37. PubMed ID: 19496709
[TBL] [Abstract][Full Text] [Related]
20. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
Gennigens C; Jerusalem G
Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
